Should I Buy AVBP? AVBP 2026 Analysis

Should You Buy ArriVent BioPharma Inc (AVBP) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

29.610

1 Day change

0.68%

52 Week Range

29.710

Analysis Updated At

2026/04/17

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

ArriVent BioPharma Inc (AVBP) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, bullish technical indicators, and favorable analyst ratings, making it a compelling choice for long-term growth.

Technical Analysis

The technical indicators are bullish. The MACD histogram is positive and expanding (0.617), RSI is overbought at 80.283, and moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200). The stock is trading above key support levels, with R2 resistance at 30.461 and current price at 29.61, suggesting upward momentum.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

The low Open Interest Put-Call Ratio indicates a bullish sentiment, while the higher Option Volume Put-Call Ratio suggests short-term bearish activity. However, the overall sentiment leans bullish due to the low open interest ratio.

Technical Summary

Sell

Buy

Positive Catalysts

Analysts have raised price targets significantly, with targets ranging from $33 to $50, and all maintaining Buy or Outperform ratings.
Positive Phase 3 trial results (WU-KONG
in a related drug class strengthen confidence in ArriVent's firmonertinib.
The FURVENT Phase 3 trial is tracking well, with potential for stronger FDA-aligned data.
The company is considered a top pick by H.C. Wainwright.

Neutral/Negative Catalysts

No recent news or significant insider/hedge fund activity, which may indicate a lack of immediate momentum.
Overbought RSI suggests the stock could face short-term pullbacks.

Financial Performance

In Q4 2025, the company showed significant improvement in financial metrics despite being pre-revenue. Net income improved by 72.27% YoY to -$35.54M, and EPS improved by 36.07% YoY to -0.83. However, the company remains unprofitable and has no revenue.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are unanimously bullish on AVBP, with multiple firms raising price targets and maintaining Buy or Outperform ratings. The average price target is significantly above the current price, reflecting strong confidence in the company's growth potential.

11 Analyst Rating

Wall Street analysts forecast AVBP stock price to rise

11 Buy

0 Hold

0 Sell

Strong Buy

Current: 29.410

Low

Averages

41.33

High

Current: 29.410

Low

Averages

41.33

High

B. Riley

Buy

maintain

$37 -> $45

AI Analysis

2026-03-23

Reason

B. Riley

Price Target

$37 -> $45

AI Analysis

2026-03-23

maintain

Buy

Reason

B. Riley raised the firm's price target on ArriVent Biopharma to $45 from $37 and keeps a Buy rating on the shares. Following Dizal's positive Phase 3 WU-KONG28 results showing sunvozertinib beat chemotherapy in 1L EGFR exon20ins non-small cell lung cancer, confidence in the EGFR TKI class has strengthened, supporting the outlook for ArriVent's firmonertinib, the analyst tells investors in a research note. Given firmonertinib's brain penetration and the more Western-weighted enrollment of the Phase 3 FURVENT trial, ArriVent could potentially deliver a stronger PFS benefit and a more FDA-aligned dataset relative to prior studies, the firm says.

BTIG

Jeet Mukherjee

Buy

initiated

$42

2026-03-11

Reason

BTIG

Jeet Mukherjee

Price Target

$42

2026-03-11

initiated

Buy

Reason

BTIG analyst Jeet Mukherjee assumed coverage of ArriVent Biopharma with a Buy rating and $42 price target. The firm says its Bay call is anchored by the FURVENT phase 3 readout that is now tracking to mid-2026 and ALPACCA phase 3 in first-line PACC - P-loop and alphaC-helix compressing - which dosed its first patient in December of 2025, the analyst tells investors in a research note. BTIG believes that the stock materially discounts a successful FURVENT outcome.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AVBP

Unlock Now

AVBP Should I Buy

AVBP Should I Buy

Should You Buy ArriVent BioPharma Inc (AVBP) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch